Washington University School of Medicine and Siteman Cancer Center, St. Louis, MO, United States.
Levine Cancer Institute, Atrium Health, Charlotte, NC, United States.
Gynecol Oncol. 2021 Jul;162(1):235-241. doi: 10.1016/j.ygyno.2021.05.003. Epub 2021 May 21.
Uterine carcinosarcoma (UCS) is a rare but aggressive cancer. In early-stage disease data guiding treatment is sparse. The purpose of this review is to summarize the findings from the 2019 NRG oncology group summer symposium meeting as well as a review of the current literature, with a particular focus on molecular targets, ongoing clinical trials, and treatment of early and advanced/recurrent disease.
A combination of expert presentations and an extensive literature search was undertaken to summarize the literature in this review. MEDLINE was queried for peer-reviewed publications on UCS. This search was not limited by year or study design, but was limited to English language publications. ClinicalTrials.gov was queried for ongoing trials in UCS.
UCS is a rare cancer that is biphasic, with the carcinomatous component driving its aggressive nature. Level 3 evidence regarding early stage disease is lacking, but retrospective data suggests adjuvant therapy is warranted. The recent results of GOG 261 have contributed valuable information towards treatment strategy, including use of paclitaxel and carboplatin for UCS. Clinical trials are ongoing to investigate new targeted agents in UCS.
Ongoing endometrial cancer clinical trials now include UCS patients. In combination with advances in molecular profiling, this will provide patients with UCS improved therapeutic options. Until that time, surgical resection and traditional cytotoxic chemotherapy remains standard of care.
子宫癌肉瘤（UCS）是一种罕见但具有侵袭性的癌症。在疾病早期，指导治疗的数据很少。本综述的目的是总结 2019 年 NRG 肿瘤学组夏季研讨会的发现，以及对当前文献的回顾，特别关注分子靶点、正在进行的临床试验以及早期和晚期/复发性疾病的治疗。
采用专家演讲和广泛的文献检索相结合的方法，对本综述中的文献进行总结。在 MEDLINE 上检索关于 UCS 的同行评议出版物。该搜索不受年份或研究设计的限制，但仅限于英文出版物。在 ClinicalTrials.gov 上查询正在进行的 UCS 临床试验。
UCS 是一种罕见的癌症，呈双相性，癌性成分决定其侵袭性。缺乏关于早期疾病的 3 级证据，但回顾性数据表明辅助治疗是必要的。GOG 261 的最新结果为治疗策略提供了有价值的信息，包括紫杉醇和卡铂在 UCS 中的应用。目前正在进行临床试验，以研究 UCS 中的新靶向药物。
目前正在进行的子宫内膜癌临床试验包括 UCS 患者。与分子谱分析的进展相结合，这将为 UCS 患者提供更好的治疗选择。在此之前，手术切除和传统细胞毒性化疗仍然是标准的治疗方法。
